The diagnosis of lung cancer is the first cause of cancer deaths for man and woman. It requires invasive procedures (at least endoscopy, transthoracic puncture, or surgery). This study is about the set up of an innovative test for lung cancer prognosis, based on biopsies and surgical material : LungCancerTest, with the creation of a start-up in progress. The main goal of this study is to approve the diagnostic value of the molecular signature of the 26 genes (LungCancerTest) revealed in blood and respiratory fluids among patients with lung cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
31
In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
UniversityHospitalGrenoble
La Tronche, France
Quantification of : DNA
From plasma or respiratory fluids, with Qiagen QIAamp MinElute Virus Spin kit. Picogreen technique (fluorimétrie) with the device Qubit 2.0 Characterization of DNA by migration on revealed agarose gel in presence of ethidium bromide Study of DNA (mutation, reassortment) with New Generation Sequencing materiel.
Time frame: Half a day
Quantification of : RNA
From plasma or respiratory fluids, with Qiagen QIAamp MinElute Virus Spin kit. Picogreen technique (fluorimétrie) with the device Qubit 2.0 Characterization of RNA with an Agilent chip Study of RNA (LungCancerTest) with PCR-Array prototype to show the expression of the molecular signature (Cancer Testis genes).
Time frame: Half a day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.